Figure 5. miR-502 inhibited colon tumor growth in vivo.
(A) 2.5 × 106 HCT116 (p53+/+) cells were subcutaneously injected into NOD/SCID mice. On days 14, 17 and 20 (indicated by arrows), miR-502 precursor (n=6) and negative miRNA (n=5) conjugated with siPORTamine reagent were delivered into tumors, and tumor sizes were measured during the treatment until day 24 when mice were sacrificed. (B) Representative images of mice bearing HCT116 tumors and (C) gross morphology of tumors after dissection at day 24 were shown. Arrows indicate the subcutaneous tumors. Scale bar: 2 cm (B) and 1 cm (C). (D) Expression level of miR-502 in tumor xenografts was quantified by real-time qRT-PCR and miR-502 injected tumors had significantly higher levels of miR-502 than the negative controls (n=3, p < 0.05).